Palisade Bio starts Phase 2b testing of ulcerative colitis drug
Palisade Bio reported on October 28, 2026 that the first participant received PALI-2108 in ASCENTRA-UC, a Phase 2b study for moderately to severely active ulcerative colitis. The randomized trial is expected to include approximately 204 patients and will compare 15 mg and 30 mg once-daily doses with placebo. Initial 12-week efficacy data are expected in the fourth quarter of 2027, followed by a 36-week maintenance period for eligible participants.
Why it matters
The study start moves PALI-2108 into a larger controlled evaluation, with the next major readout scheduled for the fourth quarter of 2027. The trial's outcome will determine whether the treatment's earlier signals can be reproduced in a broader patient population.
Key facts
- 1Palisade Bio has opened 29 of its 30 planned U.S. trial locations. stocktitan.net
- 2The global study is designed for approximately 204 patients and is progressing toward approximately 115 total sites. stocktitan.net
- 3ASCENTRA-UC will test 15 mg and 30 mg once-daily doses against placebo. stocktitan.net
- 4The study's main efficacy assessment is clinical remission at Week 12, evaluated with the Modified Mayo Score. stocktitan.net
- 5Results from the 12-week induction stage are expected in the fourth quarter of 2027. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.